Glass House Brands welcomes cannabis rescheduling and Medicare CBD pilot program

financialpost.com

Glass House Brands applauds the Trump administration's executive order rescheduling cannabis to Schedule III and authorizing a pilot program for Medicare CBD reimbursement. This action is considered the most significant drug reform in fifty years, acknowledging cannabis's medical properties and increasing access to natural relief. The company anticipates business expansion opportunities, including potential international exports and a significant role in the U.S. CBD market.


With a significance score of 5.8, this news ranks in the top 0.4% of today's 31072 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: